Why there is no single answer
Ask what semaglutide costs and the honest response is a question back: covered by what, bought through which route, and at what dose.
The spread between the cheapest and most expensive legitimate route is more than tenfold for the same molecule. Almost none of that is explained by the drug itself.
List price is not what most people pay
The list price for the weight-management product runs well over a thousand dollars a month in the United States. Almost nobody pays that number directly. It is the figure before insurance, rebates, coupons or manufacturer programmes, and it exists mostly as a starting point for negotiations you are not party to.
It still matters, because it is what you are exposed to if coverage falls through mid-treatment.
The routes, and what actually separates them
- Covered by insurance, after prior authorisation. Typically tens of dollars a month. This is by far the cheapest legitimate route and the reason the coverage question matters more than everything else on this page.
- The manufacturer's cash-pay programme, aimed at people without coverage. Several hundred dollars a month, and the pricing has changed more than once.
- Compounded through a telehealth service. Historically the cheapest non-covered route, but its availability narrowed sharply once the shortage was declared resolved, because that shortage was the legal basis for compounding copies.
- Brand retail without coverage. The list price, and the reason people look at every other row on this list.
Insurance is the whole game
Coverage for weight management specifically is inconsistent between commercial plans and frequently excluded outright. Where it exists, prior authorisation is usual and often requires documented attempts at other approaches first.
Medicare has historically been barred by statute from covering drugs used for weight loss. That changed in effect, though not in wording, once semaglutide was approved for cardiovascular risk reduction in people with established cardiovascular disease and overweight or obesity. Part D plans may cover it for that indication, which is a different thing from covering it for weight.
Medicaid coverage varies state by state, and several states have added then restricted coverage as budgets came under pressure.
The change coming in 2027
Semaglutide was selected for Medicare price negotiation under the Inflation Reduction Act, with negotiated pricing scheduled to take effect in 2027.
This is the single largest structural change on the horizon for what this drug costs in the United States. It applies directly to Medicare, and negotiated prices have historically exerted downward pressure well beyond the programme itself.
Manufacturer savings programmes and their limits
Savings cards can reduce the monthly cost substantially, but they come with conditions people discover late. They generally exclude anyone with government insurance including Medicare and Medicaid, they often cap the total benefit or the number of fills, and the terms change.
Read what the programme actually covers before building a budget on it, and check whether it still applies at your maintenance dose rather than only at the starting one.
What a year costs, not what a month costs
The advertised figure is almost always the entry price: the first month, at the starting dose, sometimes on an introductory rate.
A year is not that month repeated twelve times. The dose escalates over roughly four months, some routes price by dose, and introductory rates end. Work out the annual number across the escalation before committing, because that is the number you actually have to sustain.
And it is sustained spending rather than a one-off. Withdrawal is followed by substantial regain, so the honest planning horizon is years rather than months.
The international comparison
United States pricing for semaglutide is far above what the same product costs in other high-income countries, in some cases by an order of magnitude.
Published analyses estimating the cost of manufacturing generic semaglutide have put it dramatically below current prices. That gap is a pricing and policy question rather than a manufacturing one, and it is worth knowing when you are told the price reflects what the drug costs to make.
Practical ways to reduce what you pay
- Find out whether your plan covers weight management before choosing a route. This is worth more than every other item here combined.
- If there is a cardiovascular indication that fits your history, ask whether coverage is available on that basis.
- Ask your prescriber's office about prior authorisation support. Some practices do this routinely and well, and it materially changes approval rates.
- Check whether a manufacturer programme applies to you, and whether it still applies at maintenance dose.
- Compare the total monthly cost, not the headline. A membership fee billed separately from medication can make a cheaper-looking option more expensive.
- If a lower maintenance dose gives you the result you want, that can reduce cost on dose-priced routes. This is a conversation with a prescriber, not something to do unilaterally.
What we are not going to do on this page
We are not publishing a single headline figure for what semaglutide costs. Pricing in this category has changed repeatedly, varies by route and by dose, and any number stated flatly would be wrong for most readers within months.
The provider pages on this site carry specific figures with the date each was checked. Use those, check the date, and verify before relying on any of it.
Sources
- Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications. Obesity (Silver Spring). 2023;31(5):1270-1279.
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program, second cycle selected drug list.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
- US Food and Drug Administration. Drug shortage database, semaglutide injection.
- Wegovy (semaglutide) injection, prescribing information. Novo Nordisk.